Compare CDMOs with immunology drug manufacturing expertise for monoclonal antibodies, bispecifics, cell therapies, and immunomodulators. Filter by modality, scale, and regulatory approvals.
50 companies listed
Immunology manufacturing is at the intersection of the largest biologic drug classes. Monoclonal antibodies targeting immune pathways (anti-TNF, anti-IL-6, anti-PD-1/PD-L1) account for the majority of biologic drug revenue globally. The field continues to expand with bispecific antibodies, ADCs, CAR-T cell therapies, and next-generation immunomodulators that require increasingly specialized manufacturing capabilities.
Bispecific antibodies are the next manufacturing challenge. Unlike standard monoclonal antibodies, bispecifics (targeting two different antigens simultaneously) require novel production strategies: knobs-into-holes, CrossMab, common light chain, or tandem scFv formats. Each format has different upstream and downstream manufacturing requirements. CDMOs with experience across multiple bispecific platforms provide strategic flexibility for sponsors developing these next-generation immunotherapies.
Cell therapy manufacturing for immunological applications extends beyond oncology. CAR-T and TCR-T therapies are being developed for autoimmune diseases (lupus, multiple sclerosis), transplant rejection, and chronic infections. Manufacturing requirements are similar to oncology cell therapies -- GMP-grade viral vectors, cell processing in classified environments, cryopreservation, and patient-specific supply chain logistics -- but the scale and disease-specific modifications may differ.
Canada
Emergent BioSolutions is a specialty life sciences company with CDMO capabilities, though it has been actively pivoting away from its CDMO business. The company has sold its Baltimore-Bayview drug substance facility to Syngene and its Baltimore-Camden sterile fill/finish facility to Bora Pharmaceuticals. Emergent retains four manufacturing facilities across North America (US and Canada) and holds FDA registrations, 6 approved products, and has conducted 5 clinical trials in infectious disease. The company previously invested $75M in viral vector and gene therapy capabilities at its Canton site.
Netherlands
TAPI (Teva Active Pharmaceutical Ingredients) is the API division of Teva Pharmaceutical Industries, positioned as the world's leading international supplier of APIs with 350+ products in their portfolio. They offer integrated API and CDMO services, leveraging 85+ years of API development and manufacturing expertise. TAPI provides customized solutions including complex API development, peptide manufacturing (including GLP-1 capability), and end-to-end manufacturing. They have a partnership with Antheia for biosynthetic pharmaceutical ingredients and with Sagimet Biosciences for resmetirom API. TAPI operates globally with multiple manufacturing sites.
South Korea
Greece
Greek advanced biotechnology company focused on cell and gene therapy (CDMO activity). Subsidiary/partner of Orgenesis Inc. Designated as a priority investment in Greece in collaboration with Orgenesis. Aims to make advanced therapies accessible and affordable. Recognized as a top precision medicine solution company in Europe. Note: website has SSL certificate error and is inaccessible, so information is primarily from search results and SEC filings indicating CDMO activity for cell/tissue-based therapies.
United Arab Emirates
Life Pharma FZE (LIFEPharma) is a UAE-based pharmaceutical manufacturer and the only USFDA-approved pharmaceutical company in the United Arab Emirates. Part of VPS Healthcare, the company manufactures a wide range of generic finished dosage forms including tablets, capsules, and liquid oral preparations at its facility in Jebel Ali, Dubai. LIFEPharma is building a new oncology manufacturing facility in Abu Dhabi.
United States
Avid Bioservices, Inc. is a dedicated biologics CDMO based in Costa Mesa, California, with 30+ years of experience in mammalian cell culture-based biologics manufacturing. The company provides end-to-end drug substance and drug product services for monoclonal antibodies, bispecific antibodies, enzymes, and recombinant proteins. Avid operates from its main facility plus a new 78,000 sq ft Early Phase Center of Excellence (opened February 2026) for early-stage development. Services include cell line development, process development, analytical method development, cGMP manufacturing, and late-stage clinical and commercial biologics production. Avid has built a track record as one of the few US-based pure-play biologics CDMOs.
France
Just - Evotec Biologics (wholly owned by Evotec) is a biologics CDMO specializing in monoclonal antibodies, next-generation biologics, and biosimilar products. Differentiated by proprietary integrated end-to-end continuous manufacturing platform (J.POD) which uses perfusion cell culture with continuous purification, achieving higher output in smaller footprint than traditional batch manufacturing. Two manufacturing sites in Seattle and Redmond, WA. Offers cell line development, analytical services, process development, and early clinical through commercial cGMP manufacturing. Uses AI/ML technologies in development.
France
Biose Industrie is a French CDMO specialized in microbiome therapeutics, established in 1951. They focus on manufacturing Live Biotherapeutic Products (LBPs) and Next-Generation Probiotics (NGPs) for pharmaceutical and consumer health markets. They combine aerobic and anaerobic microbiology expertise with industrial-scale GMP manufacturing. Investing EUR 80 million to expand capacity from 8,000L to 32,000L fermentation volume at their Aurillac site. They offer full CDMO services from process development to GMP drug product manufacturing.
India
Laurus Bio is a subsidiary of Laurus Labs, an integrated research-driven biomanufacturing organization based in Bengaluru, India, with deep expertise in precision fermentation and recombinant technology. They engineer microbes as cell-factories to manufacture animal-free recombinant proteins and growth factors for biopharma, food, health, nutrition, and personal care markets. Offers precision fermentation CDMO and scale-up services, from clone development to large-scale manufacturing. Acquired as Richcore Lifesciences in 2020 and rebranded as Laurus Bio.
Germany
Rentschler Biopharma is a leading global CDMO focused exclusively on biopharmaceuticals, with over 50 years of industry experience. The company contributed to nearly 25% of FDA-approved biopharmaceuticals in 2023, has supported 180+ biotherapeutics, and serves 180+ clients worldwide. It is an independent family-owned company employing approximately 1,400 people.
China
Pharmaron is a premier life science CRO/CDMO providing comprehensive R&D and manufacturing services across the entire drug discovery to commercialization process. The company serves small molecules, biologics, ADCs, cell & gene therapies, and protein degraders. It offers laboratory services, chemistry/manufacturing/controls (CMC), clinical development, and biologics/CGT manufacturing. Pharmaron acquired a commercial API manufacturing facility in the UK and operates a gene therapy CDMO in Liverpool with a 20-year track record. The company has over 20 years of experience across 7+ facilities in the UK, US, and China.
China
ChemPartner is a science-based, technology-driven global CRO and CDMO with over 20 years of experience and 2,000+ scientists. The company provides end-to-end drug discovery through IND services for small molecules and biologics, including antibody discovery, ADC development, and cGMP biologics manufacturing. ChemPartner has expanded its biologics CDMO capabilities with a 67,000 sqm facility in Qidong, China and a new R&D center in Boston.
Canada
ACIC Pharmaceuticals Inc is a CDMO headquartered in Coral Springs, Florida, providing integrated pharmaceutical solutions from molecule to market. They offer API manufacturing, CDMO services for complex injectables including long-acting and cytotoxic injectables, regulatory support, and pharmaceutical equipment solutions. They have 249 FDA-approved products across a wide range of dosage forms.
United States
US-based comprehensive CDMO focused on advancing next-generation cell- and tissue-based therapies, from R&D to cGMP manufacturing. Located in Arcadia, California. Has partnerships with CellVax Therapeutics (first manufacturing collaboration, Phase 2 trial for FK-PC101), Pluristyx (iPSC-derived therapies), and Insight68 (Pharma 4.0 AI software). Works with iPSC, NK cells, T cells, and CAR-T for allogeneic and autologous therapies. Expanding leadership team with experienced biopharma executives.
India
Concord Biotech Limited is a leading Indian biopharmaceutical company specializing in fermentation-based API manufacturing and formulations. With over 25 years of expertise, the company manufactures 30+ APIs across immunosuppressants, oncology, and anti-infective therapeutic areas, serving 250+ global customers in 70+ countries. Concord operates four manufacturing facilities in Gujarat, India, including a new injectable manufacturing facility at Valthera producing liquid and lyophilized dosage forms.
China
Baxter International is a global medtech and biopharma company. Through its BioPharma Solutions (BPS) division, Baxter operates as a major CDMO providing sterile fill/finish manufacturing services. BPS invested over $150M in expanding sterile fill/finish capacity at its Bloomington, Indiana facility. Note: Baxter has signed a definitive agreement to divest its BioPharma Solutions business. Baxter has 308 FDA-approved products, extensive manufacturing facilities worldwide, and 93 FDA inspections on record.
Germany
ProBioGen AG is a fully integrated CDMO headquartered in Berlin, Germany, specializing in the development and GMP manufacturing of biopharmaceuticals, viral vectors, and vaccines. The company offers cell line development, process development, GMP manufacturing up to 1000L bioreactors, and comprehensive analytical services. ProBioGen leverages proprietary technologies including GlymaxX (ADCC enhancement), DirectedLuck (transposase system), and CHO.RiGHT production systems.
Italy
Orofino Pharmaceuticals Group (OPG), headquartered in Rome, Italy, is a group of companies specializing in third-party pharmaceutical manufacturing services. The group includes Biopharma (betalactam finished products), Injectalia (small sterile liquids including hormones, biologicals, heparins, vaccines), K24 Pharmaceuticals (chemical testing, EU release, secondary packaging), and Drug'On Pharma Switzerland (API manufacturing). Focused on sterile injectables and betalactam oral/injectable dosage forms.
Switzerland
Helvetic BioPharma SA is a Swiss biopharmaceutical company based in Mezzovico, Ticino, specialized in the manufacturing of biological high-value products and active compounds. The company offers CMO bioprocessing services including mammalian cell culture and microbial fermentation. Its product portfolio includes recombinant proteins, hormones, and peptides, with PEGylation capabilities for long-acting molecules.
Germany
Gesellschaft fur Micronisierung mbH (GfM) is a German-based, family-owned contract manufacturer with over 35 years of experience, specializing in micronization, milling, and particle size reduction services for the pharmaceutical industry. The company has FDA registration and has received FDA inspections. GfM provides cGMP contract manufacturing services for API intermediates and particle size engineering.
Italy
AbbVie Contract Manufacturing is an embedded CMO within AbbVie, providing third-party contract manufacturing services for over 40 years across 12 locations in the US and Europe. They offer services spanning antibody drug conjugates, aseptic fill/finish, biologics (mAbs and derivatives), custom API, eye care, hot melt extrusion, HPAPI, and oral solid dose manufacturing.
Japan
I Peace Inc. is a Palo Alto, California-based biotech CDMO specializing in cGMP manufacturing of iPSC (induced pluripotent stem cells) and iPSC-derived cell products for cell and gene therapy development. The company provides custom GMP cell manufacturing, process development, cell banking (MCB/WCB), gene editing, differentiation services, and regulatory support compliant with FDA, PMDA, and EudraLex standards. I Peace has manufactured 100+ GMP iPS cell lines and tripled its CDMO facility capacity.
United States
Grand River Aseptic Manufacturing (GRAM) is a premier US-based CDMO specializing exclusively in sterile injectable fill-and-finish services for liquid and lyophilized vials, pre-filled syringes, and cartridges. The company serves pharmaceutical and biotech clients with capabilities spanning clinical through commercial-scale production for biologics, small molecules, and vaccines. GRAM also partners with drug delivery device innovators to offer solutions for autoinjectors and on-body delivery systems.
China
WuXi Biologics is a leading global Contract Research, Development, and Manufacturing Organization (CRDMO) for biologics, with over 12,000 employees across the US, Ireland, Germany, China, and Singapore. The company provides end-to-end solutions from discovery through commercial manufacturing for biologics including monoclonal antibodies, bispecifics, ADCs, vaccines, and mRNA products using both mammalian and microbial expression systems.
Germany
Miltenyi Bioindustries (part of the Miltenyi Biotec group) is a German CDMO specializing in cell and gene therapy manufacturing. The company offers comprehensive CGT services including cell therapy process development, cell and gene therapy manufacturing, lentiviral vector production, and manufacturing technology platforms. Miltenyi has pioneered partnerships in cell and gene therapies for over 30 years and operates a global manufacturing network. The company has 2 FDA inspections on record and has conducted clinical trials in immunology and oncology.
Italy
Fresenius Kabi iPSUM S.r.l. is the Italian subsidiary of Fresenius Kabi, a global healthcare company with significant CDMO operations specializing in lifesaving medicines for critically and chronically ill patients. The company has extensive FDA-registered manufacturing facilities with 405 FDA-approved products, and provides contract development and manufacturing services for injectable, infusion, and other sterile pharmaceutical products.
United States
BioInnovatise is a US-based CDMO specializing in quick-turnaround molecular biology services for early-stage drug discovery. Services include plasmid DNA services, viral vector packaging, and CRISPR-Cas9 services. The company collaborates with researchers in government, academia, and industry, focusing on custom cloning and the early discovery phase of drug development.
United States
Akron Biotech is a leading contract manufacturing organization (CMO/CDMO) providing cGMP-compliant solutions for cell and gene therapy. The company manufactures cytokines, growth factors, media, buffers, and transfection/transduction reagents, and recently expanded to a second 60,000 sq ft biologics manufacturing facility in Sarasota, Florida, to support growing demand for ancillary materials in cell and gene therapy.
India
Aurobindo Pharma Limited is one of the world's largest vertically integrated generic pharmaceutical companies, headquartered in Hyderabad, India, operating 29 manufacturing facilities globally with capacity to produce 50+ billion formulation units and 19,000+ MT of APIs annually. Through subsidiaries Eugia Pharma Specialities (sterile injectables, oncology), CuraTeQ Biologics (biosimilars), and TheraNym Biologics, Aurobindo operates as a major CDMO. The company holds 830 US ANDA filings with 600+ approvals, and has manufacturing and packaging facilities across India, the US, Portugal, Brazil, and China. CuraTeQ received EMA GMP certification in 2024 for mammalian and microbial drug substance production, prefilled syringe and vial filling. Aurobindo's CDMO expansion includes a contract with MSD for biologics manufacturing with 15,000L bioreactors and 25-30 million vial annual capacity.
Belgium
Cellistic is a Belgium-based CDMO specializing in iPSC-based cell therapy manufacturing, positioned as a global leader in allogeneic iPSC-derived cell therapy production. The company offers full-spectrum manufacturing services including cell line development, process development, GMP manufacturing platforms, ready-to-use iPSC lines, and proprietary gene-editing capabilities. Cellistic operates Europe's first facility dedicated exclusively to iPSC-based cell therapy development and manufacturing in Mont-Saint-Guibert, Belgium.
Estonia
Icosagen is a private, science-driven biologics CRDMO headquartered in Estonia, combining CRO and CDMO capabilities under one roof. With 25 years of expertise, the company provides integrated services spanning antibody discovery, protein production, cell line development, ADC conjugation, process development, and GMP manufacturing for mammalian protein drug candidates.
Taiwan
Cenra Pharma (formerly CCPC, China Chemical & Pharmaceutical Co.) is a Taiwanese pharmaceutical company established in 1952 that develops and manufactures APIs and generic drugs, also providing CMO/CDMO services. The company has FDA and PMDA facility approvals, PIC/S GMP compliance, and offers services from API selection through formulation development and commercial manufacturing. Cenra specializes in high-potency drugs including immunosuppressants and oncology drugs, with dedicated production lines for penicillins, cephalosporins, carbapenems, and immunosuppressants.
United States
Scorpius BioManufacturing is a US-based biologics CDMO focused on mammalian, microbial, and cell therapy manufacturing. The company provides cGMP manufacturing, bioanalytical, and process development services from its San Antonio, Texas facility. Note: Tivic Health acquired manufacturing assets from Scorpius, and the company has undergone corporate restructuring under Scorpius Holdings / NightHawk Biosciences.
Argentina
Catalent is a leading global CDMO trusted by pharma, biotech, and self-care companies to accelerate the development, manufacturing, and delivery of products that improve lives. With a worldwide network of facilities, advanced technologies, and deep expertise, Catalent provides integrated end-to-end solutions spanning oral dose, biologics, specialty therapies, cell and gene therapy, and clinical supply. The company partners with innovators from early-stage design through commercial manufacturing.
Argentina
Parexel is a global contract research organization (CRO) providing clinical trial management, regulatory consulting, and biopharmaceutical development services. With over 24,000 professionals and 50+ clinical sites across five continents, the company offers Phase I-IV clinical trial services, CMC regulatory strategy, and real-world evidence generation. Parexel is primarily a CRO, not a drug manufacturer.
Canada
Apotex is Canada's largest pharmaceutical company with global operations spanning API manufacturing, finished dosage form production, and CDMO/co-development services. With capacity to produce approximately 25 billion finished doses annually and three API manufacturing sites, they serve both their own generic portfolio and external partners through Apotex Pharmachem (API CDMO) and Apotex Fermentation (fermentation-based manufacturing).
China
Jiangsu Hengrui Medicine Co., Ltd. is China's largest listed pharmaceutical company, founded in 1970, with over 20,000 employees globally. Hengrui is primarily an innovation-driven pharma company developing and manufacturing its own drugs across oncology, cardiovascular, metabolism, autoimmune, pain, and anti-infection therapeutic areas, with a pipeline of 257 drugs and 24 Class 1 innovative drugs. While it has some CDMO references in search results, Perplexity research confirms it primarily specializes in proprietary drug development and manufacturing rather than contract services.
China
KareBay Biochem (Monmouth Junction, NJ) is a custom synthesis and contract manufacturing company offering organic synthesis, peptide synthesis (including cGMP peptide synthesis), antibody production, protein expression, bioconjugation, oligonucleotide synthesis, RNA synthesis, polymer synthesis, and immunoassay services. Also sells catalog products (small molecule inhibitors, bioactive compounds, peptides, antibodies, amino acids, fluorescent dyes). Products are for research, laboratory and further evaluation purposes. cGMP peptide and organic synthesis services are explicitly offered.
India
CuraTeQ Biologics is an EU GMP-certified biopharmaceutical CDMO based in Hyderabad, India, and a subsidiary of Aurobindo Pharma. The company specializes in biosimilar development and manufacturing with a focus on oncology and immunology therapies, including monoclonal antibodies. CuraTeQ has filed multiple biosimilars with EMA and is building CDMO capabilities for contract biologics manufacturing.
India
Sun Pharmaceutical Industries Ltd. (Sun Pharma) is one of the world's largest specialty generic pharmaceutical companies, headquartered in Mumbai, India. While the company has massive manufacturing operations (1,075 FDA-approved products, 25+ FDA-registered FEI numbers), it primarily manufactures and markets its own branded and generic pharmaceutical products rather than providing contract manufacturing services to third parties as a CDMO.
Germany
Celonic is a Swiss-based 'Pure Play' biologics CDMO offering end-to-end drug substance development and manufacturing solutions for monoclonal antibodies, bispecifics, and other complex molecules. The company is a pioneer in next-generation bioprocessing technologies including process intensification and full perfusion. Celonic operates facilities in Basel, Switzerland and Heidelberg, Germany, and has a strategic alliance with CARBOGEN AMCIS for integrated ADC development and manufacturing.
China
Altruist Biologics is a China-based biologics CDMO backed by Innovent Biologics, offering end-to-end development and GMP manufacturing for monoclonal antibodies, bispecific/multispecific antibodies, fusion proteins, recombinant proteins, and antibody-drug conjugates (ADCs). The company operates large-scale facilities in Suzhou (60,000L) and Hangzhou (172,000L) with bioreactors from 1,000L to 20,000L, achieving a 99.8% batch success rate and 180+ global regulatory approvals.
France
Cell-Easy (CellEasy) is a French CDMO specializing in GMP cell therapy manufacturing, supporting academic laboratories, biotechs, and pharma companies through development and clinical programs. The company has manufactured over 1,000 clinical doses in its GMP facility and has handled 15+ cell types including T cells, NK cells, T regs, MSCs, iPSCs, and immortalized cell lines across 50+ development programs. Cell-Easy follows ICH Q2(R1), European Pharmacopoeia, EMA/MHRA, and US Pharmacopoeia standards.
United States
UI Pharmaceuticals (UIP) is the largest and most experienced university-affiliated FDA-registered pharmaceutical manufacturing facility in the United States, operated by the University of Iowa. They offer comprehensive drug product CDMO services from formulation development through commercialization. In 2023, they launched a new 16,000 sq ft sterile processing facility with fill lines. They serve pharmaceutical, biotech, pediatrics, oncology, and research organizations worldwide.
United States
Pace Life Sciences is a division of Pace Analytical Services LLC, operating as a full-service CDMO/CRO network across the United States. The company supports drug development across the entire lifecycle from preclinical research through commercialization, specializing in small molecules, biologics (proteins, peptides, monoclonal antibodies, ADCs), nucleic acids (oligonucleotides, mRNA, plasmid DNA), and gene therapies. Recognized by PharmaSource as a Top CDMO in the United States. Operates 9+ strategically located sites including a sterile fill-finish Center of Excellence in Salem, NH.
India
Aurigene Pharmaceutical Services (formerly Aurigene Services) is a leading global CRDMO with 25+ years of experience, offering integrated CRO (discovery) and CDMO services for both small and large molecules. The company provides end-to-end drug development solutions from target identification through commercial manufacturing, operating 16 USFDA-approved sites. Aurigene has 700+ scientists, 400+ completed projects, and 18 successfully commercialized NCEs. Their small molecule CDMO capabilities span drug substance development and manufacturing, formulations, and specialty areas including peptides, high potent APIs, mPEGs, steroids, carbohydrates, and flow chemistry. Their biologics division offers process development and clinical scale manufacturing for monoclonal antibodies, bispecific antibodies, and proteins, with a new biomanufacturing facility in Hyderabad.
Spain
Laboratorios Farmaceuticos ROVI S.A. is a major Spanish CDMO and pharmaceutical company, one of the leading European contract manufacturers for high-value-added injectable products. Their CDMO division (ROIS) operates three industrial complexes: two for injectables (Madrid and San Sebastian de los Reyes) and one for oral solid forms and packaging (Alcala de Henares). They also have two facilities in Granada for their own products (bemiparin and enoxaparin). ROVI's Madrid injectables plant is approved by EMA, FDA, and regulators in Korea, Brazil, and Gulf States, with ISO 9001, ISO 14001, and OSHAS certifications. They recently acquired a Bristol-Myers Squibb injectable drug product manufacturing site in Phoenix, Arizona for $250 million, expanding their capacity. ROVI provides end-to-end services from development to final product release, including clinical trials, stability studies, and analytical services. They have collaborated with Roche for manufacturing new medicines in development.
Sweden
BioInvent International AB is a clinical-stage biotech company focused on immuno-oncology antibody drug development, with an integrated contract manufacturing business unit (BioInvent Manufacturing) that has offered CDMO/CMO services since 1988. The cGMP manufacturing facility in Lund, Sweden produces monoclonal antibodies and fusion proteins using fully disposable technology in 40L to 1,000L bioreactors. Licensed by the Swedish Medical Products Agency and has French CIR accreditation. Has produced clinical-grade drug substance for trials in Europe, USA, Japan, Australia, and China.
Spain
Grifols Partnership is the CDMO arm of Grifols, a Spanish multinational with over 100 years of pharmaceutical experience, specializing in added-value small molecule injectable products manufactured in flexible bags and vials. The company operates FDA-approved manufacturing facilities and serves mid-size, large, and generic pharmaceutical companies with sterile parenteral drug products, including terminal sterilization and Form-Fill-Seal processes.
India
Corning Incorporated's Pharmaceutical Technologies division manufactures advanced glass packaging solutions for the pharmaceutical industry, most notably Valor Glass vials and containers designed for drug storage and delivery. The company is a materials science and glass technology company, not a drug manufacturer or CDMO.
Our AI Matchmaker analyzes your project requirements and matches you with qualified manufacturing partners. Free for buyers.